Neoadjuvant Inetetamab Plus Pyrotinib Phase II Trial for HER2-Positive Breast Cancer
Abstract This prospective multicenter single-arm phase II trial enrolled treatment-naive patients with stage II-III HER2-positive breast cancer to receive six cycles of neoadjuvant chemotherapy combined with the HER2-directed macromolecular agent Inetetamab and the tyrosine kinase inhibitor Pyrotinib. Between November 27, 2021, and December 18, 2025, 140 patients were enrolled, of whom 117 were evaluable for efficacy. The total pathologic complete response (tpCR; ypT0/is ypN0) rate was 61.5% (72/117; 95% CI, 52.6–70.5). The tpCR rate was significantly higher in hormone receptor (HR)-negative versus HR-positive tumors (76.2% vs 44.4%; odds ratio 0.25; 95% CI, 0.11–0.55; P < 0.001). The most common adverse events were anemia (89.2%), diarrhea (82.4%), and hypokalemia (47.3%), with grade ≥ 3 events including anemia, diarrhea, and leukopenia; no treatment-related deaths occurred. Neoadjuvant Inetetamab plus Pyrotinib with chemotherapy demonstrated clinically meaningful antitumor activity and a manageable safety profile in this population, supporting further randomized trials.
Authors
- 马兆生
- Shengnan Yao
- Ouchen Wang (ORCID: https://orcid.org/0000-0001-5230-379X)
- Yinghao Wang (ORCID: https://orcid.org/0000-0002-1315-0935)
- Chaoyi Jiang (ORCID: https://orcid.org/0009-0008-8235-9303)
- Weizhu Wu (ORCID: https://orcid.org/0000-0002-0988-4784)
- Erjie Xia (ORCID: https://orcid.org/0000-0003-0036-0703)
- Wenqian Wang (ORCID: https://orcid.org/0000-0003-2925-4306)
- Min Zheng (ORCID: https://orcid.org/0000-0002-7358-5623)
- Yiying Xu (ORCID: https://orcid.org/0000-0003-1645-4165)
- Gui-Long Guo (ORCID: https://orcid.org/0000-0002-6614-4360)
- Peipei Jiang (ORCID: https://orcid.org/0000-0002-6563-0498)
- Jingao Dai
- Jiatong Ru
- Chenghui Yang
- Duping Huang
- Chaoyue Lv
- Haiguang Liu
- Hongye Hu
- Wei Zhang
- Yizi Zheng
- Kuailu Lin
- Xuanxuan Dai
- Yupeng Liu
- Quan Li
- Weili Wu
- Siyang Dong
- Yizuo Chen
- Xue Wu
- Xiaoyang Li
- Zhiqiang Ye
- Shurong Zheng
Institutions
- Ningbo University (CN)
- Chinese Academy of Sciences (CN)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Ruian People's Hospital (CN)
- Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
- Wenzhou Central Hospital (CN)
- Ningbo Medical Center Lihuili Hospital (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-13
- DOI
- https://doi.org/10.21203/rs.3.rs-11513262/v1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- preprint